Use of DAF-displaying adenovirus vectors reduces induction of transgene-and vector-specific adaptive immune responses in mice

Human Gene Therapy

Volumn 22, Issue 9, 2011, Pages 1083-1094

  Seregin, Sergey S ^a   Aldhamen, Yasser A ^a   Appledorn, Daniel M ^a   Zehnder, Jennifer ^a   Voss, Tyler ^a   Godbehere, Sarah ^a   Amalfitano, Andrea ^a,b  

^a Michigan State University ^*  (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CAPSID PROTEIN; DECAY ACCELERATING FACTOR; GAMMA INTERFERON; N (4 METHOXYPHENYLACETYL)DEHYDROALANINE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; GENE EXPRESSION; GENE TRANSFER; IMMUNE RESPONSE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SPLEEN CELL; TRANSGENE;

ADAPTIVE IMMUNITY; ADENOVIRIDAE; ANIMALS; ANTIGENS, CD55; EPITOPES; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEK293 CELLS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; TRANSDUCTION, GENETIC; TRANSGENES;

ADENOVIRIDAE; MIRIDAE; MUS;

EID: 80053013727     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2010.218     Document Type: Article

References (49)

1. Abbink, P., Lemckert, A.A., Ewald, B.A., et al. (2007). Comparative seroprevalence and immunogenicity of six rare se-rotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 81, 4654-4663. (Pubitemid 46668663)
2. Appledorn, D.M., Kiang, A., McBride, A., et al. (2008a). Wild-type adenoviruses from groups A-F evoke unique innate immune responses, of which HAd3 and SAd23 are partially complement dependent. Gene Ther. 15, 885-901. (Pubitemid 351791476)
3. Appledorn, D.M., McBride, A., Seregin, S., et al. (2008b). Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors. Gene Ther. 15, 1606-1617.
4. Appledorn, D.M., Aldhamen, Y.A., Depas, W., et al. (2010). A new adenovirus based vaccine vector expressing an Eimeria tenella derived TLR agonist improves cellular immune responses to an antigenic target. PLoS One 5, e9579.
5. Barry, M.E., Pinto-Gonzalez, D., Orson, F.M., et al. (1999). Role of endogenous endonucleases and tissue site in transfection and CpG-mediated immune activation after naked DNA injection. Hum. Gene Ther. 10, 2461-2480. (Pubitemid 29489721)
6. Cichon, G., Boeckh-Herwig, S., Schmidt, H.H., et al. (2001). Complement activation by recombinant adenoviruses. Gene Ther. 8, 1794-1800. (Pubitemid 34100580)
7. Everett, R.S., Hodges, B.L., Ding, E.Y., et al. (2003). Liver toxi-cities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors. Hum. Gene Ther. 14, 1715-1726. (Pubitemid 38010662)
8. Fang, C., Miwa, T., Shen, H., and Song, W.C. (2007). Complement-dependent enhancement of CD8\+ T cell immunity to lympho-cytic choriomeningitis virus infection in decay-accelerating factor-deficient mice. J. Immunol. 179, 3178-3186.
9. Fischer, M.B., Ma, M., Hsu, N.C., and Carroll, M.C. (1998). Local synthesis of C3 within the splenic lymphoid compartment can reconstitute the impaired immune response in C3-deficient mice. J. Immunol. 160, 2619-2625. (Pubitemid 28136711)
10. Follenzi, A., Santambrogio, L., and Annoni, A. (2007). Immune responses to lentiviral vectors. Curr. Gene Ther. 7, 306-315. (Pubitemid 47595773)
11. Gabitzsch, E.S., Xu, Y., Yoshida, L.H., et al. (2009). Novel ade-novirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity. Vaccine 27, 6394-6398.
12. Gasque, P. (2004). Complement: a unique innate immune sensor for danger signals. Mol. Immunol. 41, 1089-1098. (Pubitemid 39345390)
13. Hartman, Z.C., Kiang, A., Everett, R.S., et al. (2007). Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo. J. Virol. 81, 1796-1812. (Pubitemid 46214453)
14. Hartman, Z.C., Appledorn, D.M., and Amalfitano, A. (2008). Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res. 132, 1-14. (Pubitemid 351232078)
15. Hawlisch, H., and Kohl, J. (2006). Complement and Toll-like receptors: key regulators of adaptive immune responses. Mol. Immunol. 43, 13-21. (Pubitemid 41021519)
16. Hensley, S.E., and Amalfitano, A. (2007). Toll-like receptors impact on safety and efficacy of gene transfer vectors. Mol. Ther. 15, 1417-1422. (Pubitemid 47099298)
17. Hensley, S.E., Cun, A.S., Giles-Davis, W., et al. (2007). Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector. Mol. Ther. 15, 393-403. (Pubitemid 46111891)
18. Hodges, B.L., Evans, H.K., Everett, R.S., et al. (2001). Adenovirus vectors with the 100K gene deleted and their potential for multiple gene therapy applications. J. Virol. 75, 5913-5920. (Pubitemid 32553121)
19. Kaufman, D.R., Liu, J., Carville, A., et al. (2008). Trafficking of antigen-specific CD8\+ T lymphocytes to mucosal surfaces following intramuscular vaccination. J. Immunol. 181, 4188-4198.
20. Kemper, C., and Atkinson, J.P. (2007). T-cell regulation: with complements from innate immunity. Nat. Rev. Immunol. 7, 9-18. (Pubitemid 46020823)
21. Kiang, A., Hartman, Z.C., Everett, R.S., et al. (2006). Multiple innate inflammatory responses induced after systemic ade-novirus vector delivery depend on a functional complement system. Mol. Ther. 14, 588-598. (Pubitemid 44296088)
22. Lasaro, M.O., and Ertl, H.C. (2009). New insights on adenovirus as vaccine vectors. Mol. Ther. 177, 1333-1339.
23. Liu, J., Ewald, B.A., Lynch, D.M., et al. (2008). Magnitude and phenotype of cellular immune responses elicited by recombi-nant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J. Virol. 82, 4844-4852. (Pubitemid 351657046)
24. Liu, J., O'Brien, K.L., Lynch, D.M., et al. (2009). Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457, 87-91.
25. Lutz, H.U., and Jelezarova, E. (2006). Complement amplification revisited. Mol. Immunol. 43, 2-12. (Pubitemid 41021518)
26. Mehlhop, E., and Diamond, M.S. (2006). Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J. Exp. Med. 203, 1371-1381. (Pubitemid 43736604)
27. Mehlhop, E., Whitby, K., Oliphant, T., et al. (2005). Complement activation is required for induction of a protective antibody response against West Nile virus infection. J. Virol. 79, 7466-7477. (Pubitemid 40756783)
28. Mingozzi, F., and High, K.A. (2007). Immune responses to AAV in clinical trials. Curr. Gene Ther. 7, 316-324. (Pubitemid 47595774)
29. Mollnes, T.E., and Kirschfink, M. (2006). Strategies of therapeutic complement inhibition. Mol. Immunol. 43, 107-121. (Pubitemid 41021527)
30. Morgan, B.P., Marchbank, K.J., Longhi, M.P., et al. (2005). Complement: central to innate immunity and bridging to adaptive responses. Immunol. Lett. 97, 171-179. (Pubitemid 40326948)
31. Ng, P., and Graham, F.L. (2002). Construction of first-generation adenoviral vectors. Methods Mol. Med. 69, 389-414.
32. Palmer, D.J., and Ng, P. (2005). Helper-dependent adenoviral vectors for gene therapy. Hum. Gene Ther. 16, 1-16. (Pubitemid 40250327)
33. Sallusto, F., Geginat, J., and Lanzavecchia, A. (2004). Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22, 745-763. (Pubitemid 38680440)
34. Schiedner, G., Hertel, S., and Kochanek, S. (2000). Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production. Hum. Gene Ther. 11, 2105-2116.
35. Seregin, S.S., and Amalfitano, A. (2009). Overcoming preexisting adenovirus immunity by genetic engineering of adenovirus-based vectors. Expert Opin. Biol. Ther. 9, 1521-1531.
36. Seregin, S.S., and Amalfitano, A. (2010). Improving adenovirus based gene transfer: strategies to accomplish immune evasion. Viruses 2, 2013-2036.
37. Seregin, S.S., Aldhamen, Y.A., Appledorn, D.M., et al. (2009a). CR1/2 is an important suppressor of adenovirus-induced innate immune responses and is required for induction of neutralizing antibodies. Gene Ther. 16, 1245-1259.
38. Seregin, S.S., Appledorn, D.M., McBride, A.J., et al. (2009b). Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy. Mol. Ther. 17, 685-696.
39. Seregin, S.S., Aldhamen, Y.A., Appledorn, D.M., et al. (2010a). Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo. Blood 116, 1669-1677.
40. Seregin, S.S., Hartman, Z.C., Appledorn, D.M., et al. (2010b). Novel adenovirus vectors 'capsid-displaying' a human complement inhibitor. J. Innate Immun. 2, 353-359.
41. Sumida, S.M., Truitt, D.M., Kishko, M.G., et al. (2004). Neutralizing antibodies and CD8\+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J. Virol. 78, 2666-2673. (Pubitemid 38314325)
42. Suresh, M., Molina, H., Salvato, M.S., et al. (2003). Complement component 3 is required for optimal expansion of CD8 T cells during a systemic viral infection. J. Immunol. 170, 788-794. (Pubitemid 36070530)
43. Tang, J., Olive, M., Pulmanausahakul, R., et al. (2006). Human CD8\+ cytotoxic T cell responses to adenovirus capsid proteins. Virology 350, 312-322. (Pubitemid 43928100)
44. Tian, J., Xu, Z., Smith, J.S., et al. (2009). Adenovirus activates complement by distinctly different mechanisms in vitro and in vivo: indirect complement activation by virions in vivo. J. Virol. 83, 5648-5658.
45. Tripathy, S.K., Goldwasser, E., Lu, M.M., et al. (1994). Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus. Proc. Natl. Acad. Sci. U.S.A. 91, 11557-11561. (Pubitemid 24356383)
46. Tripathy, S.K., Black, H.B., Goldwasser, E., and Leiden, J.M. (1996). Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat. Med. 2, 545-550.
47. Weaver, E.A., and Barry, M.A. (2008). Effects of shielding ade-noviral vectors with polyethylene glycol (PEG) on vector-specific and vaccine-mediated immune responses. Hum. Gene Ther. 19, 1369-1382.
48. Wolins, N., Lozier, J., Eggerman, T.L., et al. (2003). Intravenous administration of replication-incompetent adenovirus to rhesus monkeys induces thrombocytopenia by increasing in vivo platelet clearance. Br. J. Haematol. 123, 903-905. (Pubitemid 37533303)
49. Zaiss, A.K., and Muruve, D.A. (2005). Immune responses to adeno-associated virus vectors. Curr. Gene Ther. 5, 323-331. (Pubitemid 40895016)